| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 25002 |
| Drug | Sodium thiosulfate |
| Brand | Pedmarqsi® |
| Indication | Sodium thiosulfate (Pedmarqsi®) is indicated for the prevention of ototoxicity caused by cisplatin chemotherapy in patients one month to < 18 years of age with localised, non-metastatic, solid tumours. |
| Assessment Process | |
| Rapid review commissioned | 08/01/2025 |
| Rapid review completed | 06/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sodium thiosulfate (Pedmarqsi®) compared with the current standard of care. |
| Full HTA commissioned by the HSE | 26/03/2025 |
| Pre-submission consultation with Applicant | 16/04/2025 |
| Full submission received from Applicant | 17/06/2025 |
| Preliminary review sent to Applicant | 23/10/2025 |
| NCPE assessment re-commenced | 21/11/2025 |
| Factual accuracy sent to Applicant | 15/12/2025 |
| NCPE assessment re-commenced | 22/12/2025 |
| NCPE assessment completed | 05/01/2026 |
| NCPE assessment outcome | The NCPE recommends that sodium thiosulfate not be considered for reimbursement unless cost effectiveness can be improved*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.